Navigation Links
Mode Of Action Of The Anti-Convulsant Valproate

Researchers from Australia have recently shown, using a yeast-based in vitro bioassay for steroid hormones that valproate, a commonly used anti-convulsant for the treatment of epilepsy and bipolar disorder, is an anti-androgen and anti-progestin. //

Anti-convulsant treatment is associated with a high prevalence of reproductive dysfunction compared with age-matched non-epileptics.

The researchers examined the widely used anti-convulsants valproate (VPA) and carbamazepine (CBZ) for steroidal bioactivity using a yeast-based steroid receptor-a-galactosidase reporter assay for the androgen receptor (AR), progesterone receptor (PR) or estrogen receptor (ER).

Bioassays were performed to detect agonist activity by exposing yeast to CBZ or valproate or to detect antagonist activity by exposing yeast stimulated with testosterone, progesterone or estradiol together with either valproate or CBZ for 4 (PR) or 16 (AR, ER) hours. Valproate showed dose-dependent inhibition of progesterone-induced PR- and testosterone-induced AR activity but had no ER antagonist bioactivity and no significant PR, AR or ER agonist bioactivity.

Valproate also showed a dose-dependent blockade of DHT's suppression of AR-mediated NF-êB activation in human mammalian cells.

By contrast, CBZ had no significant PR, AR or ER agonist or AR and ER antagonist bioactivity but at the highest concentration tested it did antagonize PR activity.

The authors writing in the journal Steroids (available online 13 September 2005) conclude that valproate is a non-steroidal antagonist for human AR and PR but not ER. Valproate’s androgen and progesterone antagonism at concentrations within therapeutic blood levels seems likely to contribute to the frequency of reproductive endocrine disturbances among patients treated with valproate.
'"/>




Page: 1

Related medicine news :

1. Action of nerve cells
2. Herbs With Estrogen Action Aggravate Cancer Risk
3. Immunosuppressive Action Of Fungal Metabolite - Gliotoxin
4. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
5. Action Plan Against Drug Deaths Launched
6. Ramadoss to Take Severe Action against Fertility Clinics Conducting Stem Cell Therapy
7. UN Formulates Action Plan for Relief to Recovery in Quake-hit Areas of Pakistan
8. HIV Infected Body Parts Stolen: Biomedical Tissue Services To Face Legal Action
9. India to Implement National Action Plan against TB-HIV
10. Action Urged Against Fake Medicines
11. Supreme Court Warns Medicos of Contempt Action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... , ... Cosmetic Town, an online plastic surgery community, begins 2017 with an ... for their readers to get the information they desire. The procedures are now listed ... used on those particular areas. , “We are excited to streamline our listings in ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... doctor who administered fillers that resulted in severe facial disfiguration. After four frightening ... on by doctors at UCLA Medical Center, who removed the substances in a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: